UNSPSC 51262205: Proroxan hydrochloride

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C21H23NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 694Z9P44G4, chemically known as 1,4-benzodioxan, 6-(3-(3-phenylpyrrolidinyl)propionyl)-, hydrochloride but more generally known as proroxan hydrochloride, which bears US NIH Compound Identifier 36302. Most nations, for tariff and trade purposes, schedule proroxan hydrochloride under HS 29349990 and SITC 51579.

As of Q4 2014, PROROXAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Proroxan hydrochloride bears US NLM identifiers UMLS ID C0951999 and NCI Concept Code C84120. SMILES: C1CCC(CC1)C2CCN(C2)CCC(=O)C3CCC4C(C3)OCCO4.CL.

UNSPSC 51262205 Proroxan hydrochloride is a Commodity code that in recent state and local procurement activity names pharmaceutical products for emergency response and community health programs, though the actual opportunities posted under this code diverge significantly from the nominal product name. Seminole County, Florida has solicited naloxone (a different pharmaceutical product) and drug deactivation systems through an IFB, while the Texas Health and Human Services Commission has issued an RFI focused on direct-to-manufacturer prescription fulfillment and pharmacy benefit management — neither directly addressing proroxan hydrochloride. The code shows activity from county health departments and state health agencies pursuing pharmaceutical procurement through competitive bidding and market-intelligence gathering. Issuing bodies include county community health divisions (Seminole County) and state HHS agencies (Texas).

The two recent opportunities span different regions and procurement phases. Seminole County released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building in Sanford, Florida; the response deadline was July 26, 2023 (note: a temporal inconsistency in the source). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program targeting direct contracting between the state and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The Seminole County procurement requires E-Verify compliance, drug-free workplace certification, and specific insurance coverage; the Texas RFI seeks vendor experience with direct contracting for self-insured employers and negotiated net pricing models. Neither opportunity specifies set-aside designations or funding amounts.